

6-25-07

A.F
AF
Iew

Express Mail Label No.: EV942367360US
Date of Deposit: June 21, 2007

Attorney Docket Number: 24852-513



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Bacopoulos et al. CONFIRMATION NUMBER: 9840
SERIAL NUMBER: 10/692,523 EXAMINER: Cybille Delacroix-Muirheid
FILING DATE: October 24, 2003 ART UNIT: 1614
FOR: METHODS OF TREATING CANCER WITH HDAC INHIBITORS

MAIL STOP AF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Cited Reference B16;
4. Check Number 3854 in the amount of \$180.00; and
5. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (212) 935-3000.

The Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24852-513. Please address all correspondence to Customer No. 35437. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Dated: June 21, 2007

Michelle A Iwamoto

Ivor Elrifi, Reg. No. 39,529
Michelle A. Iwamoto, Reg. No. 55,296
Attorneys for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS, *et al.*
666 Third Avenue, 24th Floor
New York, New York 10017
Phone: (212) 935-3000
Fax: (212) 983-3115



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Bacopoulos et al. CONF. NO.: 9840
 SERIAL NUMBER: 10/692,523 EXAMINER: Cybille Delacroix-Muirheid
 FILING DATE: October 24, 2003 ART UNIT: 1614
 FOR: METHODS OF TREATING CANCER WITH HDAC INHIBITORS

MAIL STOP AF
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the document listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, a copy of which is submitted herewith.

This Supplemental Information Disclosure Statement is being filed after the three months of the U.S. filing date, and after the mailing date of a Final Action, but before the Notice of Allowance under 37 C.F.R. 197(c). Accordingly, attached is our check in the amount of \$180.00 in payment of the fee under 37 C.F.R. 1.17(p).

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims. It is also respectfully requested that the Examiner initial, sign and date, and return a copy of the signed modified Form PTO-1449 with the next U.S. PTO communication, to evidence that the cited information has been fully considered by the U.S. Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

180.00 00

06/26/2007 HUONG1 00000004 10692523

01 FC:1806

Applicants: Bacopoulos *et al.*
U.S.S.N.: 10/692,523
Express Mail Label No.: EV942367360US
Date of Deposit: June 21, 2007

Attorney Docket No.: 24852-513

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

The Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. **50-0311** Ref. No. **24852-513**. Please address all correspondence to Customer No. **35437**.

Respectfully submitted,


Dated: June 21, 2007

Michelle A Iwamoto

Ivor Elrifi, Reg. No. 39,529
Michelle A. Iwamoto, Reg. No. 55,296
Attorneys for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS, *et al.*
666 Third Avenue, 24th Floor
New York, New York 10017
Phone: (212) 935-3000
Fax: (212) 983-3115

Express Mail Label No.: EV942367360US
Date of Deposit: June 21, 2007

PAGE 1 of 1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Modified Form 1449/PTO		Application Number	10/692,523
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	October 24, 2003
		First Named Inventor	Bacopoulos
		Group Art Unit / Conf. No.	1614 / 9840
		Examiner Name	Cybille Delacroix-Muirheid
		Attorney Docket Number	24852-513

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No
	B16	WO 2005/023179	Aton Pharma, Inc.; Sloan-Kettering Institute for Cancer Research	March 17, 2005	X

NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.